Area of research
Oncology · Genetics
Research interest
Research interests include CAR-T cell therapy research, Virus-based gene therapy research, CRISPR and Genetic Engineering, and Immunodeficiency and Autoimmune Disorders.
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.
Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease
Are entirely virus-free CAR T cells as good as lentiviral transduced universal cells?
Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy.
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Clinical development of allogeneic chimeric antigen receptor αβ-T cells.
Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.
Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’ Immunotherapy
Base edited “universal” donor CAR T cell strategies for acute myeloid leukaemia
CD62L-selected umbilical cord blood universal CAR T cells
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.
Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma.
Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Cytosine Deaminase Base Editing to Restore <i>COL7A1</i> in Dystrophic Epidermolysis Bullosa Human: Murine Skin Model.
Non-osteopenic Bone Pathology After Allo-hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity.
CAR T cells to fight acute myeloid leukaemia
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Genome-Edited T Cell Therapies.
CAR T cells to fight T cell leukaemia
Base-edited CAR T cells for combinational therapy against T cell malignancies.
Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery.
FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency.
Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency.
Genome editing of therapeutic T cells.
A FOXN1 mutation competitively displaces wild-type FOXN1 from higher-order nuclear condensates to cause immunodeficiency
The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.